
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About
Edesa Biotech Inc (EDSA)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: EDSA (1-star) is a SELL. SELL since 4 days. Profits (-3.21%). Updated daily EoD!
1 Year Target Price $10.33
1 Year Target Price $10.33
1 | Strong Buy |
0 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -40.71% | Avg. Invested days 33 | Today’s Advisory SELL |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 15.89M USD | Price to earnings Ratio - | 1Y Target Price 10.33 |
Price to earnings Ratio - | 1Y Target Price 10.33 | ||
Volume (30-day avg) 1 | Beta 0.27 | 52 Weeks Range 1.55 - 5.00 | Updated Date 08/15/2025 |
52 Weeks Range 1.55 - 5.00 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.24 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-08 | When - | Estimate -0.5 | Actual -0.25 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -40.22% | Return on Equity (TTM) -69.64% |
Valuation
Trailing PE - | Forward PE 0.17 | Enterprise Value 14869782 | Price to Sales(TTM) 120477.93 |
Enterprise Value 14869782 | Price to Sales(TTM) 120477.93 | ||
Enterprise Value to Revenue 128525.38 | Enterprise Value to EBITDA -1.25 | Shares Outstanding 7029750 | Shares Floating 3595042 |
Shares Outstanding 7029750 | Shares Floating 3595042 | ||
Percent Insiders 28.55 | Percent Institutions 30.1 |
Upturn AI SWOT
Edesa Biotech Inc
Company Overview
History and Background
Edesa Biotech Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing innovative treatments for inflammatory and immune-related diseases. Founded in 2011, the company has pursued a strategy of identifying and developing promising clinical-stage assets. Key milestones include securing patents, completing clinical trials, and seeking regulatory approvals.
Core Business Areas
- Pharmaceutical Development: Focuses on the development of pharmaceutical products targeting inflammatory and immune-related diseases. This includes clinical trials and regulatory submissions.
Leadership and Structure
The company is led by a management team with experience in drug development and commercialization. The organizational structure includes departments for research and development, clinical operations, and regulatory affairs.
Top Products and Market Share
Key Offerings
- EB05 (sebudiazone): A monoclonal antibody being developed for Acute Respiratory Distress Syndrome (ARDS). Currently in clinical development. Market share is currently 0 as no sales have been reported. Competitors include companies developing ARDS treatments, such as those focusing on ventilator management and other pharmacological interventions. Approval is not yet granted by the FDA.
- Cryptococcus neoformans Diagnostic Test: Diagnostic test is under development. Market share is currently 0 as no sales have been reported. Competitors include companies such as Thermo Fisher Scientific (TMO).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and significant competition. Demand is driven by aging populations, increasing prevalence of chronic diseases, and advances in medical technology.
Positioning
Edesa Biotech Inc. is positioning itself as a developer of niche therapies for inflammatory and immune-related diseases, often focusing on areas with unmet medical needs. Competitive advantages could include novel mechanisms of action and successful clinical trial outcomes.
Total Addressable Market (TAM)
TAM is difficult to estimate due to the specific indications and clinical stage of its products. However, the global market for ARDS treatments is estimated to be in the billions of dollars. The company's positioning within this TAM depends on successful clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Proprietary technology and intellectual property
- Experienced management team
- Focus on unmet medical needs
- Potential for breakthrough therapies
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- High regulatory risk
- Lack of commercialized products
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Successful clinical trial results
- Regulatory approvals and commercialization
Threats
- Competition from larger pharmaceutical companies
- Failure to achieve clinical trial endpoints
- Regulatory setbacks
- Changes in healthcare policies
Competitors and Market Share
Key Competitors
Competitive Landscape
Edesa Biotech Inc. faces competition from larger pharmaceutical companies with more resources. Its competitive advantage lies in its focus on niche therapies and innovative approaches.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by expansion of the pipeline and progression of clinical trials.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization. Analyst estimates vary widely due to the uncertainty of drug development.
Recent Initiatives: Recent initiatives include advancing clinical trials for EB05 and seeking partnerships to fund further development.
Summary
Edesa Biotech Inc. is a high-risk, high-reward biopharmaceutical company focused on developing treatments for inflammatory and immune-related diseases. While the company has promising clinical-stage assets, it faces significant challenges in securing funding, achieving clinical trial success, and obtaining regulatory approvals. Successful development and commercialization of its pipeline could lead to substantial growth, but failure in any of these areas could negatively impact the company. Edesa needs to look out for competition and changes in healthcare policies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Press releases
- Third-party market research reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on your own due diligence and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Edesa Biotech Inc
Exchange NASDAQ | Headquaters Markham, ON, Canada | ||
IPO Launch date 2015-11-05 | CEO, Company Secretary & Director Dr. Pardeep Nijhawan FRCPC, M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 16 | Website https://www.edesabiotech.com |
Full time employees 16 | Website https://www.edesabiotech.com |
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.